Global Immunoprotein Diagnostic Testing Market Overview:
Immunoprotein diagnostic testing market is expected to gain market growth in the forecast period due to a surging volume of patients suffering from chronic as well as infectious diseases and increasing demand for early diagnostic services. Immunoprotein diagnostic testing detects the level of proteins in the body, and thereby, it helps in the diagnosis of diseases. An increasing number of infectious diseases and lifestyle-induced health conditions has been the leading driver for the immunoprotein diagnostic testing market.
- Increase in Incidence & Prevalence of Infectious and Chronic Diseases
- Rising Geriatric Population Coupled with a High Prevalence of Non- Communicable Diseases
- Technological Advancements in Immunodiagnostic Instruments Introduction of Novel Automated Systems
- High Cost of Diagnosis and Unaffordability of Low-Income Patients
- Surging Development in the Condition-Specific Assays & Tests
- Increasing Need for Early Diagnosis in the Emerging Economies
- Complex Regulatory Framework for the Approval of Various Immunoprotein Diagnostic Tests
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Abbott Laboratories (United States), Abcam PLC (United Kingdom), Bio-Rad Laboratories (United States), Danaher Corporation (United States), Diasorin (Italy), Roche Diagnostics (Switzerland), Beckman Coulter (United States), F. Hoffman-La Roche Ltd. (Switzerland) and Siemens Healthineers (Germany). Additionally, following companies can also be profiled that are part of our coverage like A. Menarini Diagnostics (Italy), Affymetrix (United States) and Agilent Technologies (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Immunoprotein Diagnostic Testing market by 2026. Considering Market by Technology, the sub-segment i.e. Radioimmunoassay will boost the Immunoprotein Diagnostic Testing market. Considering Market by End User, the sub-segment i.e. Laboratories will boost the Immunoprotein Diagnostic Testing market.
Latest Market Insights:
In June 2019, Eurobio scientific entered into an exclusive negotiation with Vivo medical group for the acquisition of Pathway Diagnostics Ltd and Personal Diagnostics Ltd, two British companies specializing respectively in the development and distribution of in vitro diagnostic tests in the U.K and Ireland, and self-tests for consumers and professionals via an e-commerce platform.
In April 2019, Meridian Bioscience Inc., a provider of diagnostics solutions and raw material, entered into a definitive agreement to acquire the business of GenoPic Inc., a provider of molecular diagnostic instruments and assays. With this acquisition, Meridian will be getting GenePOCís state-of-the-art revenue molecular diagnostics platform, which offers samples to result in testing for single tests, as well as flexible multiplexing capability.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Immunoprotein Diagnostic Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Immunoprotein Diagnostic Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Immunoprotein Diagnostic Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.